You are here: Industry Insights > Psoriasis

News List

Inflammation Linked to Thyroid Dysfunction in Psoriasis Patients drugs
December 31, 2019
While the rate of thyroid dysfunction among patients with psoriasis generally is not higher than expected, psoriasis in patients with thyroid dysfunction is more clinically severe and ...
Palmoplantar Pustulosis Confirmed as Orphan Disease drugs
December 26, 2019
Co-occurring psoriasis is common among patients with palmoplantar pustulosis (PPP), according to a study published in the November issue of the British Journal of Dermatology.
Type 2 Diabetes More Common in Patients With Psoriasis drugs
December 12, 2019
Rates of type 2 diabetes may be higher among patients with psoriasis, according to a study published online in the Journal of the European Academy of Dermatology and Venereology.
Psoriasis Independently Linked to Increased Mortality Risk drugs
August 28, 2019
Psoriasis is significantly associated with an increased mortality risk, according to a study published online in the Journal of the American Academy of Dermatology.
Amgen to acquire Otezla® for $13.4 billion in cash worldpharmanews
August 27, 2019
Amgen announced today that it has entered into an agreement with Celgene Corporation in connection with its previously announced merger with Bristol-Myers Squibb Company to acquire...
Eli Lilly’s Taltz outperforms Janssen’s Tremfya in psoriasis pharmaceutical-technology
August 15, 2019
Eli Lilly has announced that its drug Taltz (ixekizumab) outperformed rival Janssen’s Tremfya in the Phase VI IXORA-R trial studying patients with moderate-to-severe plaque psoriasis.
Biologic Tx for Psoriasis May Reduce Coronary Inflammation drugs
August 01, 2019
For patients with moderate-to-severe psoriasis, the perivascular fat attenuation index (FAI)...
AbbVie's psoriasis launch Skyrizi hitting stride ahead of FDA's decision on upadacitinib fiercepharma
July 29, 2019
AbbVie is in the early stages of its Humira biosimilar slide after European copycats rolled out last fall. But thankfully for the drugmaker, it has a psoriasis launch handily besting expectations.
NICE recommends risankizumab to treat severe psoriasis europeanpharmaceuticalreview
July 15, 2019
NICE has issued a recommendation for risankizumab to treat patients with severe plaque psoriasis.
Competition in the RMB3 Billion Psoriasis Drug Market Turning White-hot! PharmaSources/Caicai
July 10, 2019
J & J’s “Best Psoriasis Drug” Guselkumab Applied for Marketing in China

Previous page 1 2 3 4 5 6 7 8 9 10 Next page